Piramal Pharma Solutions extended its robust CDMO capabilities to George Medicines to develop WIDAPLIK. WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial ...
Widaplik is a single tablet, triple combination therapy for hypertension that is expected to be available in the fourth quarter of 2025. The Food and Drug Administration (FDA) has approved Widaplik ™ ...
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one-third of the adult population. This disorder is characterized by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results